CVS Health is steering its ship back on course, exceeding expectations and reinforcing its financial forecasts, a strong signal that its ambitious turnaround strategy is gaining traction!
It's been a challenging journey, but the latest quarterly report from CVS Health paints a picture of resilience and progress. The healthcare giant has not only surpassed Wall Street's predictions for both earnings and revenue in the fourth quarter but has also confidently reaffirmed its profit outlook for 2026. This is fantastic news for investors and a clear indicator that the company's comprehensive plan to revitalize its operations is bearing fruit.
CVS CFO Brian Newman shared in an interview, "'24 was a tough year for the company. So '25 righted the ship." This sentiment highlights the significant shift in momentum the company is experiencing.
Looking Ahead: Solid Financial Projections
For the full year, CVS anticipates its profit to land between $7.00 and $7.20 per share. This range aligns perfectly with the $7.17 per share that analysts, according to LSEG, had projected. This consistency is a testament to the company's ability to forecast and manage its financial performance effectively.
Furthermore, CVS is maintaining its 2026 revenue guidance, aiming for at least $400 billion. While analysts currently estimate revenue at $409.77 billion, it's worth noting that these figures might not fully capture all the potential headwinds Newman mentioned. He indicated that the guidance incorporates approximately $20 billion in headwinds. Interestingly, about half of this is attributed to the company's strategic decision to exit the Affordable Care Act (ACA) individual exchange market this year. The other half stems from the retail sector adapting to lower drug prices, a direct result of the recent "most favored nation" deals negotiated by President Donald Trump with numerous pharmaceutical companies.
Navigating Drug Pricing and Partnerships
CVS has been actively participating in initiatives to lower drug costs. Last week, the company announced that its nearly 9,000 pharmacies are now accepting discount cards from the newly launched TrumpRx direct-to-consumer platform for eligible patients. Newman emphasized CVS's alignment with the Trump administration's goal of cost reduction, stating, "CVS shares the Trump administration's goal of reducing costs." He further explained that these lower prices establish a new baseline, empowering Caremark, CVS's pharmacy benefit manager, to negotiate even more favorable rates for its clients, suggesting a collaborative rather than adversarial approach to cost management.
Key Growth Drivers Identified
CVS expects its growth trajectory for the current year to be significantly boosted by the return to target margins within its recovering Aetna insurance business, particularly its privately run Medicare Advantage plans, and by the performance of Caremark. The company is also seeing positive developments with its primary-care provider, Oak Street Health, which is reportedly "improving its profitability" this year. This follows the closure of 16 underperforming Oak Street locations. For the retail pharmacy segment, several factors are contributing to its strength, including new technological investments and the strategic acquisition of locations and customers from Rite Aid after its bankruptcy filing last year.
Investor Confidence and Stock Performance
Investors have clearly responded positively to CVS's strategic direction. Under the leadership of CEO David Joyner, who took the helm in late 2024, the company has undertaken a significant restructuring to address years of underperformance. These efforts, including cost-cutting measures, leadership realignments, and exiting less profitable markets, have fueled a remarkable 40% surge in the company's stock price over the past year.
A Closer Look at the Fourth Quarter Results:
Here's a breakdown of CVS's fourth-quarter performance compared to Wall Street's expectations:
- Earnings per share (EPS): $1.09 adjusted (beating the expected 99 cents)
- Revenue: $105.69 billion (exceeding the expected $103.59 billion)
CVS reported a net income of $2.92 billion, or $2.30 per share, for the fourth quarter. This represents a substantial increase from the $1.62 billion, or $1.30 per share, recorded in the same period last year. Adjusted earnings, excluding specific items like restructuring charges and capital losses, stood at $1.09 per share for the quarter.
Total sales for the fourth quarter reached $105.69 billion, marking an impressive 8.2% increase year-over-year. This growth was broad-based, with all three of CVS's business segments contributing positively.
Segment-Specific Performance Highlights:
Insurance Business: This segment generated $36.29 billion in revenue, a jump of over 10% compared to the fourth quarter of 2024. Newman described the quarter as "very strong" and anticipates continued margin improvement, largely driven by Medicare Advantage. The company is on track to achieve its target margins of 3% to 4% for this business by 2028.
- But here's where it gets complex: Aetna and other insurers have faced challenges with higher-than-anticipated medical costs as more Medicare Advantage patients seek procedures delayed during the pandemic. While these costs remain elevated, insurers like Aetna and UnitedHealthcare appear to be developing better strategies to manage them. Newman cautioned, "we will continue the elevated trends. ... I don't think it's too early to assume anything other than a prudent outlook."
- The medical benefit ratio (a key indicator of profitability) for the insurance segment remained stable at 94.8%. A lower ratio signifies that a company collects more in premiums than it pays out in benefits. The primary driver for this ratio in the fourth quarter was Medicaid pass-through payments received in late December.
- The government business within this unit saw improved performance, but this was somewhat offset by shifts in Medicare drug cost timing due to changes under the Inflation Reduction Act, which altered typical prescription spending patterns.
- And this is the part most people miss: Just last month, Medicare Advantage insurers saw their stock prices dip after the Trump administration proposed nearly flat government payment rates for these plans in 2027. Newman expressed his belief that these proposed rates don't fully reflect the actual medical cost trends and confirmed that CVS is actively engaging in discussions with the Centers for Medicare and Medicaid Services (CMS) before the final rate notice is issued in early April.
Pharmacy and Consumer Wellness Division: This segment posted $37.66 billion in sales, an increase of 12.4% from the previous year. This growth was partly fueled by higher prescription volumes, including those acquired from Rite Aid. However, it was partially tempered by pharmacy reimbursement pressures and the market entry of some generic drugs.
Health Services Segment: This unit generated $51.24 billion in revenue, up 9% compared to the same quarter in 2024. This segment encompasses Caremark, which plays a crucial role in negotiating drug discounts, developing formularies (lists of covered medications), and processing pharmacy reimbursements.
What do you think about CVS's strategy to navigate drug pricing and its impact on the healthcare landscape? Does the company's exit from the ACA individual market raise concerns for you? Share your thoughts in the comments below!
